A phase II prospective study of sequential myeloablative chemotherapy with hematopoietic stem cell rescue for the treatment of selected high risk and recurrent central nervous system tumors

Amy Rosenfeld, Morris Kletzel, Reggie Duerst, David Jacobsohn, Paul Haut, Joanna Weinstein, Alfred Rademaker, Colleen Schaefer, Lauren Evans, Molly Fouts, Stewart Goldman

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

High risk/recurrent CNS tumors have a poor prognosis. We studied tandem high dose chemotherapy (HDC) with hematopoietic progenitor stem cell rescues (HPCR) as potentially curative therapy. Twenty-four patients (mean age 6.8 years) were enrolled, 19 underwent HDC/HPCR. Diagnoses were medulloblastoma (n = 9), germ cell tumor (n = 4), high grade astrocytoma (n = 2), supratentorial PNET (n = 1), pineoblastoma (n = 2), or papillary meningioma (n = 1). Cytoreduction regimen #1 consisted of carboplatin (500 mg/m2) 9 3 days, etoposide (250 mg/m2) 9 3 days, and thiotepa (300 mg/m2) 9 3 days. Patients without progression or excessive toxicity (n = 11), received regimen &has2 with melphalan (60 mg/m2) 9 3 days and cyclophosphamide (1,500 mg/m2) 9 4 days. Projected overall/event-free survival for the 19 patients was 51/37% and 34/28% at 1 and 5 years, respectively. Toxicity was significant with six treatment related deaths including four with veno-occlusive disease. This regimen of sequential HDC/HPCR in high risk/recurrent CNS tumor patients is not feasible due to toxicity.

Original languageEnglish
Pages (from-to)247-255
Number of pages9
JournalJournal of Neuro-Oncology
Volume97
Issue number2
DOIs
StatePublished - Apr 2010

Fingerprint

Central Nervous System Neoplasms
Hematopoietic Stem Cells
Prospective Studies
Drug Therapy
Therapeutics
Pinealoma
Thiotepa
Primitive Neuroectodermal Tumors
Medulloblastoma
Melphalan
Germ Cell and Embryonal Neoplasms
Carboplatin
Astrocytoma
Meningioma
Etoposide
Cyclophosphamide
Disease-Free Survival
Neoplasms

Keywords

  • Chemotherapy
  • Hematopoietic stem cell rescue
  • Myeloablative
  • Pediatric high risk and brain tumors
  • Pediatric recurrent brain tumors

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

A phase II prospective study of sequential myeloablative chemotherapy with hematopoietic stem cell rescue for the treatment of selected high risk and recurrent central nervous system tumors. / Rosenfeld, Amy; Kletzel, Morris; Duerst, Reggie; Jacobsohn, David; Haut, Paul; Weinstein, Joanna; Rademaker, Alfred; Schaefer, Colleen; Evans, Lauren; Fouts, Molly; Goldman, Stewart.

In: Journal of Neuro-Oncology, Vol. 97, No. 2, 04.2010, p. 247-255.

Research output: Contribution to journalArticle

Rosenfeld, Amy ; Kletzel, Morris ; Duerst, Reggie ; Jacobsohn, David ; Haut, Paul ; Weinstein, Joanna ; Rademaker, Alfred ; Schaefer, Colleen ; Evans, Lauren ; Fouts, Molly ; Goldman, Stewart. / A phase II prospective study of sequential myeloablative chemotherapy with hematopoietic stem cell rescue for the treatment of selected high risk and recurrent central nervous system tumors. In: Journal of Neuro-Oncology. 2010 ; Vol. 97, No. 2. pp. 247-255.
@article{d5c20aea7e1a4b99aff2c89e077a5871,
title = "A phase II prospective study of sequential myeloablative chemotherapy with hematopoietic stem cell rescue for the treatment of selected high risk and recurrent central nervous system tumors",
abstract = "High risk/recurrent CNS tumors have a poor prognosis. We studied tandem high dose chemotherapy (HDC) with hematopoietic progenitor stem cell rescues (HPCR) as potentially curative therapy. Twenty-four patients (mean age 6.8 years) were enrolled, 19 underwent HDC/HPCR. Diagnoses were medulloblastoma (n = 9), germ cell tumor (n = 4), high grade astrocytoma (n = 2), supratentorial PNET (n = 1), pineoblastoma (n = 2), or papillary meningioma (n = 1). Cytoreduction regimen #1 consisted of carboplatin (500 mg/m2) 9 3 days, etoposide (250 mg/m2) 9 3 days, and thiotepa (300 mg/m2) 9 3 days. Patients without progression or excessive toxicity (n = 11), received regimen &has2 with melphalan (60 mg/m2) 9 3 days and cyclophosphamide (1,500 mg/m2) 9 4 days. Projected overall/event-free survival for the 19 patients was 51/37{\%} and 34/28{\%} at 1 and 5 years, respectively. Toxicity was significant with six treatment related deaths including four with veno-occlusive disease. This regimen of sequential HDC/HPCR in high risk/recurrent CNS tumor patients is not feasible due to toxicity.",
keywords = "Chemotherapy, Hematopoietic stem cell rescue, Myeloablative, Pediatric high risk and brain tumors, Pediatric recurrent brain tumors",
author = "Amy Rosenfeld and Morris Kletzel and Reggie Duerst and David Jacobsohn and Paul Haut and Joanna Weinstein and Alfred Rademaker and Colleen Schaefer and Lauren Evans and Molly Fouts and Stewart Goldman",
year = "2010",
month = "4",
doi = "10.1007/s11060-009-0009-z",
language = "English",
volume = "97",
pages = "247--255",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - A phase II prospective study of sequential myeloablative chemotherapy with hematopoietic stem cell rescue for the treatment of selected high risk and recurrent central nervous system tumors

AU - Rosenfeld, Amy

AU - Kletzel, Morris

AU - Duerst, Reggie

AU - Jacobsohn, David

AU - Haut, Paul

AU - Weinstein, Joanna

AU - Rademaker, Alfred

AU - Schaefer, Colleen

AU - Evans, Lauren

AU - Fouts, Molly

AU - Goldman, Stewart

PY - 2010/4

Y1 - 2010/4

N2 - High risk/recurrent CNS tumors have a poor prognosis. We studied tandem high dose chemotherapy (HDC) with hematopoietic progenitor stem cell rescues (HPCR) as potentially curative therapy. Twenty-four patients (mean age 6.8 years) were enrolled, 19 underwent HDC/HPCR. Diagnoses were medulloblastoma (n = 9), germ cell tumor (n = 4), high grade astrocytoma (n = 2), supratentorial PNET (n = 1), pineoblastoma (n = 2), or papillary meningioma (n = 1). Cytoreduction regimen #1 consisted of carboplatin (500 mg/m2) 9 3 days, etoposide (250 mg/m2) 9 3 days, and thiotepa (300 mg/m2) 9 3 days. Patients without progression or excessive toxicity (n = 11), received regimen &has2 with melphalan (60 mg/m2) 9 3 days and cyclophosphamide (1,500 mg/m2) 9 4 days. Projected overall/event-free survival for the 19 patients was 51/37% and 34/28% at 1 and 5 years, respectively. Toxicity was significant with six treatment related deaths including four with veno-occlusive disease. This regimen of sequential HDC/HPCR in high risk/recurrent CNS tumor patients is not feasible due to toxicity.

AB - High risk/recurrent CNS tumors have a poor prognosis. We studied tandem high dose chemotherapy (HDC) with hematopoietic progenitor stem cell rescues (HPCR) as potentially curative therapy. Twenty-four patients (mean age 6.8 years) were enrolled, 19 underwent HDC/HPCR. Diagnoses were medulloblastoma (n = 9), germ cell tumor (n = 4), high grade astrocytoma (n = 2), supratentorial PNET (n = 1), pineoblastoma (n = 2), or papillary meningioma (n = 1). Cytoreduction regimen #1 consisted of carboplatin (500 mg/m2) 9 3 days, etoposide (250 mg/m2) 9 3 days, and thiotepa (300 mg/m2) 9 3 days. Patients without progression or excessive toxicity (n = 11), received regimen &has2 with melphalan (60 mg/m2) 9 3 days and cyclophosphamide (1,500 mg/m2) 9 4 days. Projected overall/event-free survival for the 19 patients was 51/37% and 34/28% at 1 and 5 years, respectively. Toxicity was significant with six treatment related deaths including four with veno-occlusive disease. This regimen of sequential HDC/HPCR in high risk/recurrent CNS tumor patients is not feasible due to toxicity.

KW - Chemotherapy

KW - Hematopoietic stem cell rescue

KW - Myeloablative

KW - Pediatric high risk and brain tumors

KW - Pediatric recurrent brain tumors

UR - http://www.scopus.com/inward/record.url?scp=77950458480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950458480&partnerID=8YFLogxK

U2 - 10.1007/s11060-009-0009-z

DO - 10.1007/s11060-009-0009-z

M3 - Article

VL - 97

SP - 247

EP - 255

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -